IBIO may be used in ZMapps production
21.10.14 10:44
#302
Money is King
iBio
Read the damn S1 wink Aspire was allocated up to 23,418,172 shares to raise "x" amount of money, they had issued 1.8m of these as of Oct. 1, and there is nothing to suggest they would need to issue all of the stock... Aspire is the underwriter, they work in the best interest of iBio, not themselves wink let's not fear monger too much...
As of October 1, 2014, there were 65,642,095 shares of our common stock outstanding (28,253,959 shares held by non-affiliates) excluding the 1,818,172 shares offered that have been issued to Aspire Capital and the additional 21,600,000 shares that may be issuable to Aspire Capital pursuant to the Purchase Agreement. If all of such 23,418,172 shares of our common stock offered hereby were issued and outstanding as of the date hereof, such shares would represent 26.29% of the total common stock outstanding or 45.3% of the non-affiliate shares of common stock outstanding as of the date hereof. The number of shares of our common stock ultimately offered for sale by Aspire Capital is dependent upon the number of shares purchased by Aspire Capital under the Purchase Agreement.
Pursuant to the Purchase Agreement and the Registration Rights Agreement, we are registering 23,418,172 shares of our common stock under the Securities Act, which includes the Commitment Shares and Initial Purchase Shares that have already been issued to Aspire Capital and 21,600,000 shares of common stock which we may issue to Aspire Capital after this registration statement is declared effective under the Securities Act. All 23,418,172 shares of common stock are being offered pursuant to this prospectus.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10238463
As of October 1, 2014, there were 65,642,095 shares of our common stock outstanding (28,253,959 shares held by non-affiliates) excluding the 1,818,172 shares offered that have been issued to Aspire Capital and the additional 21,600,000 shares that may be issuable to Aspire Capital pursuant to the Purchase Agreement. If all of such 23,418,172 shares of our common stock offered hereby were issued and outstanding as of the date hereof, such shares would represent 26.29% of the total common stock outstanding or 45.3% of the non-affiliate shares of common stock outstanding as of the date hereof. The number of shares of our common stock ultimately offered for sale by Aspire Capital is dependent upon the number of shares purchased by Aspire Capital under the Purchase Agreement.
Pursuant to the Purchase Agreement and the Registration Rights Agreement, we are registering 23,418,172 shares of our common stock under the Securities Act, which includes the Commitment Shares and Initial Purchase Shares that have already been issued to Aspire Capital and 21,600,000 shares of common stock which we may issue to Aspire Capital after this registration statement is declared effective under the Securities Act. All 23,418,172 shares of common stock are being offered pursuant to this prospectus.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10238463
22.10.14 12:16
#306
dm69
pre-market -- 1,83$
http://www.nasdaq.com/symbol/ibio/premarket
22.10.14 14:34
#307
aktivdepot
pre market 1,93US$ ;-))
http://www.stockwatch.com/Quote/Detail.aspx?symbol=IBIO®ion=U
22.10.14 14:35
#308
aktivdepot
News
http://www.stockwatch.com/News/...141022&symbol=IBIO®ion=U
iBio Expands Exclusive Product Collaboration With Novici Biotech
2014-10-22 08:31 ET - News Release
NEWARK, DE -- (Marketwired) -- 10/22/14
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch platform with Novici's patented GRAMMR® technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.
In April 2013, iBio announced the achievement of a technology transfer milestone when Novici was able to use the iBioLaunch system in a challenge study, without any involvement of iBio, to reliably replicate production of commercial yields of targeted biotherapeutics and vaccines. An additional benchmark was achieved in a second live-fire study in May 2013 when Novici used iBioLaunch technology to produce a recombinant vaccine candidate for H7N9 influenza within 21 days of receiving initial antigen sequence information from iBio. Subsequently, the two companies have worked together on iBio-proprietary and third party antibody product candidates addressing both chronic therapy and acute infectious disease treatment.
Novici has previously applied GRAMMR technology successfully for gene and protein optimization to rapidly increase the expression yields of certain target products without alteration of the structure and function of the proteins themselves. By increasing the efficiency with which a desired product can be manufactured, without changing the characteristic of the product or established downstream purification processes, manufacturing capacity of existing facilities can be increased when needed to address pandemic or bioterrorism threats or other urgent needs without the costs and time required to enlarge existing or build additional facilities.
About Novici Biotech, LLC
Novici is a private biotechnology company offering proprietary synthetic biology tools and directed evolution capabilities to advance the product-focused goals of clients in the pharmaceutical, agricultural, and industrial fields. Novici's patented GRAMMR® technology for high-resolution genetic reassortment enhances gene functionality at both the nucleotide and protein level. Novici is focused on bringing to market its unique synthetic biology technologies, including the means to empirically optimize the codon usage structure of any gene to endow it with optimal expression yield, protein folding integrity, and cell type compatibility, and to optimize protein structure and function for commercial use. For more information, please visit the company's website: www.novicibiotech.com.
About iBio, Inc.
iBio owns the iBioLaunch platform, which is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch platform. The company also offers technology licenses to others and provides collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. Further information is available at: www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
iBio Expands Exclusive Product Collaboration With Novici Biotech
2014-10-22 08:31 ET - News Release
NEWARK, DE -- (Marketwired) -- 10/22/14
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch platform with Novici's patented GRAMMR® technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.
In April 2013, iBio announced the achievement of a technology transfer milestone when Novici was able to use the iBioLaunch system in a challenge study, without any involvement of iBio, to reliably replicate production of commercial yields of targeted biotherapeutics and vaccines. An additional benchmark was achieved in a second live-fire study in May 2013 when Novici used iBioLaunch technology to produce a recombinant vaccine candidate for H7N9 influenza within 21 days of receiving initial antigen sequence information from iBio. Subsequently, the two companies have worked together on iBio-proprietary and third party antibody product candidates addressing both chronic therapy and acute infectious disease treatment.
Novici has previously applied GRAMMR technology successfully for gene and protein optimization to rapidly increase the expression yields of certain target products without alteration of the structure and function of the proteins themselves. By increasing the efficiency with which a desired product can be manufactured, without changing the characteristic of the product or established downstream purification processes, manufacturing capacity of existing facilities can be increased when needed to address pandemic or bioterrorism threats or other urgent needs without the costs and time required to enlarge existing or build additional facilities.
About Novici Biotech, LLC
Novici is a private biotechnology company offering proprietary synthetic biology tools and directed evolution capabilities to advance the product-focused goals of clients in the pharmaceutical, agricultural, and industrial fields. Novici's patented GRAMMR® technology for high-resolution genetic reassortment enhances gene functionality at both the nucleotide and protein level. Novici is focused on bringing to market its unique synthetic biology technologies, including the means to empirically optimize the codon usage structure of any gene to endow it with optimal expression yield, protein folding integrity, and cell type compatibility, and to optimize protein structure and function for commercial use. For more information, please visit the company's website: www.novicibiotech.com.
About iBio, Inc.
iBio owns the iBioLaunch platform, which is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch platform. The company also offers technology licenses to others and provides collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. Further information is available at: www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
22.10.14 14:53
#309
Money is King
tsja leute!
Man muss halt auch mal dicke Eier beweisen...und auch mal halten können... ;-) sollten heute die 3$ zurück holen... Lets goooo!
22.10.14 15:33
#310
dr.soldberg
denk ich nicht ...obwohl ich hier auch
massiv inv. bin. die news ist ein non event
22.10.14 18:12
#312
Money is King
close
über 2$ wäre wichtig...Vllt.gibts ja noch ein EOD run Richtung 2.20-2.50?!
22.10.14 20:34
#315
dannyo
au au au
ich habe mir auch ordentlich die finger verbrannt - mal abwarten wie sich das entwickelt.
23.10.14 01:44
#316
Money is King
ich glaub
weiterhin an iBio und eine Hammer NEWS! Jetzt verkaufen macht kein Sinn! Vllt. nicht diese Woche ...aber hoffentlich bald! Es muss endlich ein Mittel gegen dieses scheiß Ebola produziert werden... und iBio hat gute Karten!
http://investorshub.advfn.com/boards/...msg.aspx?message_id=107452729
http://investorshub.advfn.com/boards/...msg.aspx?message_id=107453142
http://investorshub.advfn.com/boards/...msg.aspx?message_id=107452729
http://investorshub.advfn.com/boards/...msg.aspx?message_id=107453142
23.10.14 14:30
#317
Money is King
Ebola Verdacht in Oberhausen
http://mobil.mz-web.de/panorama/...-oberhausen,23886370,28827508.html
23.10.14 16:33
#319
fab24
Nur wieder ein´Artikel wo der Autor
auf sein Shortinteresse hinweist.
Scheint wieder zu klappen
http://finance.yahoo.com/tumblr/...fecting-buyers-with-140522823.html
Scheint wieder zu klappen
http://finance.yahoo.com/tumblr/...fecting-buyers-with-140522823.html
23.10.14 16:40
#321
fab24
Wie kommst du auf 0,81 Cent?
Tief war 1,29 $, das sind bei mir im Umrechner knapp 1 €.
23.10.14 16:43
#323
Weltenbummler
Danach sehen wir die 0,45 bis 0,50 Euro. Oh graus
Was für ein jammer.
23.10.14 18:31
#325
martin30sm
jetzt mal noch etwas runter und dann
mit voller Energie rauf zu alten Höhen!
Kann jederzeit wieder durchstarten!
Kann jederzeit wieder durchstarten!